Trials / Terminated
TerminatedNCT02175654
Regorafenib as Single Agent in Patients With Metastatic Colorectal Cancer (mCRC) With Any RAS or BRAF Mutation Previously Treated With FOLFOXIRI Plus Bevacizumab
Phase II Study of Regorafenib as Single Agent for the Treatment of Patients With Metastatic Colorectal Cancer (mCRC) With Any RAS or BRAF Mutation Previously Treated With FOLFOXIRI Plus Bevacizumab
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 15 (actual)
- Sponsor
- Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the efficacy of single-agent regorafenib in the second-line treatment in metastatic colorectal cancer with any RAS or BRAF mutation previously treated with FOLFOXIRI plus bevacizumab in terms of progression-free survival at 6 months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Regorafenib |
Timeline
- Start date
- 2014-06-01
- Primary completion
- 2016-02-01
- Completion
- 2016-02-01
- First posted
- 2014-06-26
- Last updated
- 2017-08-01
Locations
1 site across 1 country: Spain
Source: ClinicalTrials.gov record NCT02175654. Inclusion in this directory is not an endorsement.